Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Earnings Data
Report Date
Mar 11, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.05Last Year’s EPS
-0.67Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted the strong performance and strategic advancements of MIPLYFFA, particularly its revenue contribution and expansion into the European market. However, the company faces challenges with OLPRUVA and slow enrollment in the DiSCOVER trial. Despite these challenges, the financial position remains robust, supporting future strategic goals.Company Guidance
Strong Performance of MIPLYFFA
Third quarter net revenue reached $26.1 million, driven by $22.4 million from MIPLYFFA. Additionally, there were 8 new prescription enrollment forms received in the quarter, bringing the total to 137 since MIPLYFFA became commercially available a year ago.
European Market Expansion
A Marketing Authorization Application (MAA) has been filed with the European Medicines Agency for MIPLYFFA, and the application has been validated and is under review. The potential of expanding into the European market could significantly increase the patient base.
Patent and Market Access Progress
Zevra has established a solid patent position for MIPLYFFA and requested a patent term extension with the U.S. Patent and Trademark Office. Covered lives for MIPLYFFA increased to 66% in the third quarter, reflecting strong market access development.
Robust Financial Position
As of September 30, 2025, total cash, cash equivalents, and investments were $230.4 million, an increase of $12.7 million compared to the end of Q2 2025. The company believes available financial resources are sufficient to execute on strategic priorities.
ZVRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZVRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $10.07 | $9.09 | -9.73% |
Aug 12, 2025 | $11.76 | $9.43 | -19.81% |
May 13, 2025 | $7.87 | $8.14 | +3.43% |
Mar 11, 2025 | $8.07 | $7.92 | -1.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zevra Therapeutics (ZVRA) report earnings?
Zevra Therapeutics (ZVRA) is schdueled to report earning on Mar 11, 2026, TBA (Confirmed).
What is Zevra Therapeutics (ZVRA) earnings time?
Zevra Therapeutics (ZVRA) earnings time is at Mar 11, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZVRA EPS forecast?
ZVRA EPS forecast for the fiscal quarter 2025 (Q4) is 0.05.